Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
News|Videos|June 23, 2025
First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase
Author(s)Cesar Augusto Perez, MD
Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.
Advertisement
Advertisement
Related to this article
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to aLutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The TrueBeam photon therapy system has been added to the Statesir Cancer Center at Atlantic Health CentraState Medical Center.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Advertisement
Advertisement
Trending on OncLive
1
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
2
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
3
FDA Grants Final Approval to Lutetium Lu 177 Dotatate Biosimilar for SSTR+ GEP-NETs
4
FDA Approves Generic Lanreotide Injection for GEP-NETs
5